KR20240068762A - 중수소화 돔페리돈을 함유하는 제제 - Google Patents

중수소화 돔페리돈을 함유하는 제제 Download PDF

Info

Publication number
KR20240068762A
KR20240068762A KR1020247014648A KR20247014648A KR20240068762A KR 20240068762 A KR20240068762 A KR 20240068762A KR 1020247014648 A KR1020247014648 A KR 1020247014648A KR 20247014648 A KR20247014648 A KR 20247014648A KR 20240068762 A KR20240068762 A KR 20240068762A
Authority
KR
South Korea
Prior art keywords
domperidone
pharmaceutical formulation
gastroparesis
formulation
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247014648A
Other languages
English (en)
Korean (ko)
Inventor
피유쉬 파텔
캐서린 피어스
조나단 이삭손
Original Assignee
신돔 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신돔 파마, 인크. filed Critical 신돔 파마, 인크.
Publication of KR20240068762A publication Critical patent/KR20240068762A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020247014648A 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제 Pending KR20240068762A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862750491P 2018-10-25 2018-10-25
US62/750,491 2018-10-25
KR1020217015511A KR20210080495A (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제
PCT/US2019/058033 WO2020086947A1 (en) 2018-10-25 2019-10-25 Formulations containing deuterated domperidone

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015511A Division KR20210080495A (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제

Publications (1)

Publication Number Publication Date
KR20240068762A true KR20240068762A (ko) 2024-05-17

Family

ID=68582416

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247014648A Pending KR20240068762A (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제
KR1020217015511A Ceased KR20210080495A (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제
KR1020237041657A Active KR102667995B1 (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217015511A Ceased KR20210080495A (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제
KR1020237041657A Active KR102667995B1 (ko) 2018-10-25 2019-10-25 중수소화 돔페리돈을 함유하는 제제

Country Status (12)

Country Link
US (2) US12514852B2 (https=)
EP (1) EP3668510B1 (https=)
JP (2) JP7583728B2 (https=)
KR (3) KR20240068762A (https=)
CN (1) CN113164463B (https=)
AU (1) AU2019366993B2 (https=)
CA (1) CA3117682A1 (https=)
ES (1) ES2852623T3 (https=)
IL (1) IL282575B (https=)
SG (1) SG11202103284QA (https=)
WO (1) WO2020086947A1 (https=)
ZA (1) ZA202102115B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712432A (zh) * 2016-02-04 2023-09-08 辛多美制药有限公司 氘代多潘立酮组合物、方法和制备物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240068762A (ko) 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
EP4525868A1 (en) * 2022-04-20 2025-03-26 CinDome Pharma, Inc. Deuterated domperidone for treating gastroparesis
CN120813355A (zh) * 2023-03-23 2025-10-17 辛多美制药有限公司 用于治疗糖尿病性胃轻瘫的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702392D0 (en) 1997-02-06 1997-03-26 Boots Co Plc Therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
CN1686128A (zh) * 2005-04-19 2005-10-26 北京正大绿洲医药科技有限公司 多潘立酮滴丸及其制备方法
AU2008245580A1 (en) 2007-04-26 2008-11-06 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone
CN102125528A (zh) 2010-01-12 2011-07-20 上海中邦斯瑞生物药业技术有限公司 多潘立酮口崩片
DE102010015143A1 (de) * 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
WO2017136617A1 (en) * 2016-02-04 2017-08-10 Cinrx Pharma, Llc Deuterated domperidone compositions and methods for therapy of disorders
KR20240068762A (ko) 2018-10-25 2024-05-17 신돔 파마, 인크. 중수소화 돔페리돈을 함유하는 제제
WO2020086950A1 (en) 2018-10-25 2020-04-30 Cindome Pharma, Inc. Formulations containing domperidone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712432A (zh) * 2016-02-04 2023-09-08 辛多美制药有限公司 氘代多潘立酮组合物、方法和制备物

Also Published As

Publication number Publication date
KR20210080495A (ko) 2021-06-30
JP7652751B2 (ja) 2025-03-27
US12514852B2 (en) 2026-01-06
CN113164463B (zh) 2022-09-20
KR102667995B1 (ko) 2024-05-23
NZ774559A (en) 2025-02-28
JP7583728B2 (ja) 2024-11-14
IL282575B (en) 2022-05-01
EP3668510A1 (en) 2020-06-24
CN113164463A (zh) 2021-07-23
JP2022512041A (ja) 2022-02-01
EP3668510B1 (en) 2021-01-13
WO2020086947A1 (en) 2020-04-30
US20220110929A1 (en) 2022-04-14
AU2019366993B2 (en) 2024-02-15
ZA202102115B (en) 2023-10-25
ES2852623T3 (es) 2021-09-14
JP2023036663A (ja) 2023-03-14
IL282575A (en) 2021-06-30
CA3117682A1 (en) 2020-04-30
US20260083717A1 (en) 2026-03-26
SG11202103284QA (en) 2021-05-28
AU2019366993A1 (en) 2021-05-06
KR20230169456A (ko) 2023-12-15
BR112021007754A2 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
JP7652751B2 (ja) 重水素化ドンペリドンを含む製剤
EP2164572B2 (en) Carbamoyl-cyclohexanes for treating acute mania
AU2024202861A1 (en) Formulations containing domperidone
RU2796537C2 (ru) Составы, содержащие дейтерированный домперидон
CA2627544A1 (en) Formulations of quinolinones for the treatment of cancer
US20250282775A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2010047361A1 (ja) 腸管吸収性を改善する医薬組成物
HK40033044B (en) Formulations containing deuterated domperidone
HK40033044A (en) Formulations containing deuterated domperidone
BR112021007754B1 (pt) Formulações contendo domperidona deuterada e uso das mesmas
HK40033468A (en) Formulations containing domperidone
HK40033468B (en) Formulations containing domperidone
BR112021007755B1 (pt) Formulações contendo domperidona e uso das mesmas

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000